Wall Street expects a year-over-year decline in earnings on higher revenues when ANI Pharmaceuticals (ANIP) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 8, 2024, might help the stock move higher if these key numbers are bett ...

PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ: ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date Friday, Novem ...

Company Overview - ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, particularly for diseases with high unmet medical needs [2] - The company aims to achieve sustainable growth by scaling its Rare Disease business, enhancing its Generics business through improved research and development, and leveraging its U.S.-based manufacturing capabilities [2] Recent Developments - ANI Pharmaceuticals announced the launch of Estradiol Gel, 0.06%, following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) [1] - Estradiol Gel, 0.06% is the generic version of the reference listed drug EstroGel® Gel, 0.06% [1] - The U.S. annual sales for Estradiol Gel, 0.06% are approximately $16.7 million based on August 2024 moving annual total (MAT) IQVIA data [1]

PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will present new pre-clinical data highlighting its membranous nephropathy (MN) research during two poster presentations at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, CA, October 23-27. "We are excited to share our data with the ASN 2024 community. These data shed light of the potential role of melanocortin receptors in the underlying ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering ANI Pharmaceuticals (ANIP) , which belongs to the Zacks Medical - Biomedical and Genetics industry.When looking at the last two reports, this drugmaker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 16.57%, on average, in the last two quarters.For the last reported quarter, ANI came out with earnings of $1.0 ...

Piper Sandler has initiated coverage on ANI Pharmaceuticals ANIP, an integrated specialty pharmaceutical firm that develops and markets branded and generic medicines.The analyst notes that ANI’s business model has significantly transformed, shifting from a primary emphasis on generics to a new focus on integrating high-margin brand assets aimed at rare diseases. Cortrophin Gel (adrenocorticotropic hormone (ACTH)), the company’s lead asset, has been the centerpiece of that evolution.Cortrophin gel sales more ...

Biotech Forum Discussion - The Biotech Forum has been focused on lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months [1] - The forum offers real-time trading ideas and insights from seasoned biotech investors [1] ANI Pharmaceuticals Spotlight - ANI Pharmaceuticals Inc (NASDAQ: ANIP) is highlighted as a small but growing biopharma company [1] - The equity is considered one of the few reasonable growth at a reasonable price (GARP) stocks in the biotech sector [1] The Biotech Forum Services - The Biotech Forum provides a model portfolio featuring 12-20 high upside biotech stocks [1] - The forum offers live chat for discussing trade ideas, weekly research, and option trades [1] - Market commentary and portfolio updates are provided every weekend [1]

ANI Pharmaceuticals (ANIP) closed the last trading session at $56.79, gaining 2.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $81.20 indicates a 43% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $13.70. While the lowest estimate of $60 indicates a 5.7% increase from the current price level, the most optimistic analyst e ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.Zacks has develo ...

PRINCETON, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Ketoconazole Shampoo, 2%. ANI’s Ketoconazole Shampoo, 2% is the generic version of the reference listed drug (RLD) Nizoral®. "We are proud to announce the FDA approval and commercialization of Ketoconazole Shampoo, 2%, another limite ...